

# 1 Values and preferences in COVID-19 public health guidelines: A

## 2 systematic review

3 Sarah Kirsh

4 *Departments of Anesthesia and Health Research Methods, Evidence, and Impact*  
5 *McMaster University, Hamilton, ON*

6 Michael Ling

7 *Departments of Anesthesia*  
8 *McMaster University, Hamilton, ON*

9 Tanvir Jassal

10 *Departments of Anesthesia*  
11 *McMaster University, Hamilton, ON*

12 Tyler Pitre

13 *Division of Respiriology, Department of Medicine*  
14 *University of Toronto*

15 Thomas Pigott

16 *Department of Health Research Methods, Evidence, and Impact*  
17 *McMaster University, Hamilton, ON*

18 *Department of Family Medicine,*  
19 *Queens University, Kingston, ON*

20 Dena Zeraatkar\*

21 *Departments of Anesthesia and Health Research Methods, Evidence, and Impact*  
22 *McMaster University, Hamilton, ON*

23

24 \*Corresponding author:

25 **Disclaimers:** None.

26 **Funding:** None.

27 **Data:** We will make all data publicly accessible upon the publication of this manuscript on Open Science  
28 Framework (<https://osf.io/aup36/>).

29 **Acknowledgements:** None.

30 **Authors' Contributions:** DZ conceived the idea. SK, ML, and TJ collected data. SK and ML synthesized  
31 data and produced descriptive characteristics. SK, TP, and DZ wrote the first draft of the manuscript. All  
32 authors reviewed, provided critical feedback on the manuscript, and approved the final version of the  
33 manuscript.

34

35 **Word count:** 4,975

36 **Tables:** 3

37 **Figures:** 2



39 **Abstract**

40

41 **Background:** Internationally accepted standards for trustworthy guidelines include the necessity to  
42 ground recommendations in values and preferences. Considering values and preferences respects the  
43 rights of citizens to participate in health decision-making and ensures that guidelines align with the  
44 needs and priorities of the communities they are intended to serve. Early anecdotal reports suggest that  
45 COVID-19 public health guidelines did not consider values and preferences.

46 **Objective:** To capture and characterize whether and how COVID-19 public health guidelines considered  
47 values and preferences.

48 **Methods:** We performed a systematic review of COVID-19 public health guidelines. We searched the  
49 eCOVID19 RecMap platform—a comprehensive international catalog of COVID-19 guidelines—up to July  
50 2023. We included guidelines that made recommendations addressing vaccination, masking, isolation,  
51 lockdowns, travel restrictions, contact tracing, infection surveillance, and school closures. Reviewers  
52 worked independently and in duplicate to review guidelines for consideration of values and preferences.

53 **Results:** Our search yielded 129 eligible guidelines, of which 43 (33.3%) were published by national  
54 organizations, 73 (56.6%) by international organizations, and 14 (10.9%) by professional societies and  
55 associations. Twenty-six (20.2%) guidelines considered values and preferences. Among guidelines that  
56 considered values and preferences, most did so to assess the acceptability of recommendations (23;  
57 88.5%) and by referencing published research (24; 92.3%). Guidelines only occasionally engaged  
58 laypersons as part of the guideline development group (6; 23.1%). None of the guidelines performed  
59 systematic reviews of the literature addressing values and preferences.

60 **Conclusion:** Most COVID-19 public health guidelines did not consider values and preferences. When  
61 values and preferences were considered, it was suboptimal. Disregard for values and preferences in  
62 guidelines might have partly contributed to divisive and unpopular COVID-19 policies. Given the  
63 possibility of future health emergencies, we recommend guideline developers identify efficient methods  
64 for considering values and preferences in crisis situations.

## 65 **Background**

66 Public health guidelines provide recommendations intended to optimize population health (1). They are  
67 typically published by professional associations and authoritative organizations, examples of which  
68 include the World Health Organization (WHO) and the US Centers for Disease Control and Prevention  
69 (CDC). The impact of public health guidelines is wide-reaching and diverse—they inform national  
70 policies, rules and regulations at schools and workplaces, and messaging to which the public is exposed.  
71 Given their significant impact, it is essential for these guidelines to be credible and effective.

72 For guidelines to be considered credible, they must adhere to certain standards (2-12). Considering  
73 public values and preferences—defined as the public’s perspectives, beliefs, expectations, and goals for  
74 health and life—is internationally recognized as a critical component of credible guideline development  
75 (2, 3, 10). Considering values and preferences respects the rights of citizens to participate in health  
76 decision-making, aligns guidelines with the needs and priorities of the communities they are intended to  
77 serve, ensures recommendations are logistically feasible and acceptable, and improves support for the  
78 recommendations (13, 14). Values and preferences may vary by country or setting, and therefore may  
79 be an important lens for contextualizing or adapting guidance between settings (15).

80 While some public health professionals and decision-makers may argue that scientific evidence alone  
81 should inform recommendations, trustworthy guideline development necessitates the synthesis of both  
82 scientific evidence and values and preferences to arrive at recommendations (2, 3, 10). Guideline  
83 developers face decisions that invariably involve trade-offs between benefits and harms. For example, a  
84 new lung cancer screening program might improve survival rates through early detection but could also  
85 result in overdiagnosis, false positives, radiation, and divert resources from other healthcare services,  
86 potentially increasing morbidity and mortality from other causes. Ideally, the public's values and  
87 preferences should guide the assessment of whether the benefits of a given action outweigh its harms.

88 For these reasons, nearly all organizations that establish standards for guideline development advise  
89 that guidelines also consider values and preferences (2, 3, 10, 16). For example, the AGREE II tool, the  
90 gold standard tool for evaluating the quality of guidelines, includes a domain addressing the  
91 consideration of values and preferences (3). Likewise, the GRADE Evidence-to-Decision frameworks, the  
92 most commonly used frameworks for formulating recommendations, include values and preferences as  
93 a key consideration (10).

94 Guideline developers may incorporate public values and preferences in several ways, such as involving  
95 laypersons as part of the guideline development group, reviewing published research on public values  
96 and preferences, conducting de novo studies, and providing the public the opportunity to comment on  
97 draft recommendations (2, 3, 10, 14, 17-22). Ideally, guideline developers should perform systematic  
98 reviews of the literature addressing values and preferences (19, 23, 24). In situations in which guideline  
99 developers are unable to find sufficient high-quality evidence, they can perform de novo surveys and  
100 focus groups to generate this information. While insights and beliefs of the guideline development  
101 group, especially if it includes laypersons, are valuable, they may not fully capture the broader public's  
102 values and preferences, leaving some uncertainty.

103 The COVID-19 pandemic caused significant threats to health globally. In response, governments  
104 implemented policies, informed by public health guidelines, that ranged from stringent measures to  
105 curb transmission, including “lockdowns”, to attempts that focused on minimizing disruptions to daily  
106 life (25-28). Public health professionals, and ultimately politicians, were confronted with the delicate,  
107 ethically complex task of balancing COVID-19 with other public health problems and social and  
108 economic well-being. Ideally, public values and preferences should have informed this trade-off.

109 Early anecdotal reports, however, suggest that public engagement was limited and suboptimal in COVID-  
110 19 public health guidelines (29). In France, for example, the public was not consulted about lockdowns  
111 (30). In Germany, early decisions were made only by a handpicked group of scientific experts (31, 32).  
112 While rigorous guidelines that considered values and preferences may have been possible, the  
113 unprecedented circumstances posed by the COVID-19 pandemic may have adversely impacted guideline  
114 development methods and thus guideline quality. Nevertheless, consideration of values and preferences  
115 remains important even in crisis situations (33, 34). Even guidance for producing guidelines during  
116 emergency situations requires consideration of values and preferences (33). Suboptimal consideration  
117 of values and preferences might have contributed to divisive and unpopular policies, the erosion of trust  
118 in public health, and limited compliance (35-40).

119 As the pandemic evolves from an acute threat to a long-term public health challenge, now is a critical  
120 time to evaluate and learn from our response. While the COVID-19 pandemic was unprecedented, we  
121 anticipate other health emergencies that will also benefit from credible guidelines that are aligned with  
122 societal values. We conducted a systematic review of national and international public health COVID-19  
123 guidelines to capture and characterize whether and how they considered public values and preferences.

## 124 **Methods**

125 We report our systematic review of COVID-19 public health guidelines following the Preferred Reporting  
126 Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines for systematic reviews  
127 (41). Figure 1 presents an overview of our methods.

### 128 ***Search strategy and screening***

129 We intended to include a representative sample of national and international COVID-19 public health  
130 guidelines. We anticipated that a search of research databases would identify few eligible guidelines,  
131 since most guidelines are typically published on webpages or reports from national and professional  
132 organizations instead of journals. Thus, to identify eligible guidelines, we searched the eCOVID19-19  
133 RecMap—a comprehensive open-access digital collection of COVID-19 guidelines and recommendations,  
134 developed in collaboration between Cochrane Canada, the WHO Collaborating Center for Infectious  
135 Diseases, and the Guidelines International Network, up to July 2023 (42, 43).

136 The eCOVID19-19 RecMap presents thematically organized lists of recommendations contained in  
137 COVID-19 guidelines. Following training and calibration to ensure sufficient agreement, two reviewers  
138 worked independently and in duplicate to screen all recommendations catalogued in the eCOVID19  
139 RecMap for eligibility. When reviewers identified an eligible recommendation, they included the  
140 guideline containing that recommendation in the present systematic review. Reviewers resolved  
141 discrepancies by discussion, or when necessary, by adjudication with a third reviewer.

142 We supplemented our search by reviewing webpages of national and international guideline producing  
143 organizations (i.e., WHO, US CDC, and European Centers for Disease Control) and reviewing the  
144 references of the included guidelines.

#### 145 ***Eligibility criteria***

146 We included national and international guidelines that contained one or more COVID-19 public health  
147 recommendations. We defined guidelines as documents that described themselves as ‘guidelines’ or as  
148 providing recommendations. Distinguishing between clinical practice and public health guidelines is  
149 challenging and guidelines may include a combination of clinical practice and public health  
150 recommendations. To address this issue, we pragmatically defined public health recommendations as  
151 recommendations addressing interventions aimed at the population level instead of at the individual  
152 patient level or recommendations that are motivated by population effects (e.g., staying home when  
153 sick to prevent spread of COVID-19, lockdowns, closure of educational institutions).

154 We recognized that not all recommendations will require consideration of values and preferences. For  
155 example, the benefits of a particular course of action may obviously and overwhelmingly outweigh  
156 potential harms, or vice versa, such that the consideration of values and preferences is unimportant (44,  
157 45). For example, the potential benefits of hand washing overwhelmingly outweigh any potential harms  
158 such that a recommendation to practice frequent handwashing does not require consideration of values  
159 and preferences. We restricted eligibility to guidelines that made recommendations addressing topics  
160 that we considered to be sensitive to values and preferences: vaccination, masking, isolation,  
161 lockdowns, travel restrictions, contact tracing, infection surveillance, and school closures. Our selection  
162 of these topics was informed by scientific discourse and discussions in social and traditional media. Box  
163 1 describes how recommendations addressing these topics are sensitive to values and preferences.

#### **Box 1: Description of the ways in which recommendations addressing select topics require consideration of values and preferences**

Recommendations addressing vaccination will require weighing the benefits of vaccination such as prevention of COVID-19 adverse health outcomes against its adverse effects, like myocarditis and blood clots. While this may be straightforward with older or medically fragile populations, it is more nuanced for younger populations who are at lower risk of COVID-19 complications (46).

Recommendations addressing isolation, lockdowns, and other infection control measures necessitate weighing immediate benefits of reducing transmission against broader health, social, and economic consequences (47, 48).

Recommendations addressing closure of educational institutions must weigh educational achievement and the social value of schooling against the goal of reducing community COVID-19 transmission (49, 50).

Surveillance and contact tracing must balance the advantage of preventing COVID-19 transmission against individual privacy rights, medical confidentiality, and potential data breaches (49-51).

164

165 For feasibility, we excluded regional guidelines. We also excluded guidelines addressing the care of  
 166 patients with COVID-19, the operation of healthcare facilities, performance of diagnostic tests for  
 167 COVID-19, care of patients with comorbidities during the pandemic, management of long covid, and  
 168 niche professional activities (e.g., care of heritage collections during COVID-19).

169 When guidelines were updated, resulting in multiple versions, we included all versions in our study. This  
 170 approach allowed us to study how consideration of values and preferences may have evolved during the  
 171 course of the pandemic.

172 **Data extraction**

173 Following training and calibration to ensure sufficient agreement, two reviewers worked independently  
 174 and in duplicate and used a pilot-tested structured form to collect information on guideline  
 175 characteristics, methods, and values and preferences.

176 We intended to capture whether and how guidelines considered public values and preferences. We  
 177 used a broad operationalization of values and preferences, defined as public’s perspectives, beliefs,  
 178 expectations, and goals for health and life, including but not limited to soliciting insights from laypersons  
 179 as part of the guideline development process or as part of the dissemination process, assessing  
 180 acceptability and tolerability of potential courses of action, and weighing benefits and harms (2, 3, 10).

181 The Armstrong framework for patient engagement in guideline development informed the type of data  
 182 that we collected (18). This framework contains 10 categories describing the steps of the guideline  
 183 development process in which values and preferences may be considered, 37 categories describing the  
 184 purpose of considering values and preferences, and 36 categories describing methods by which values  
 185 and preferences may be considered (18). Box 2 presents an overview of the framework. While this  
 186 framework was originally conceived for patient engagement in clinical practice guidelines, our  
 187 examination suggests it is also equally relevant for public health guidelines. We created new categories  
 188 when we encountered scenarios not included in the framework.

<b>Box 2: Overview of the Armstrong framework for patient engagement in guidelines with example categories (18)</b>	
<b>Values &amp; preferences</b>	<b>Example categories</b>
<b>Step in guideline development process in which values and preferences may be considered</b>	<ul style="list-style-type: none"> <li>- Nominating guideline topics</li> <li>- Developing recommendations</li> <li>- Disseminating and implementing recommendations</li> </ul>
<b>Purpose of considering values and preferences</b>	<ul style="list-style-type: none"> <li>- Identify topics that are important to patients, caregivers, and the community</li> <li>- Assist in translating evidence-based conclusions into meaningful, clear, and respectful recommendations</li> <li>- Endorse guidelines from patient perspective</li> </ul>
<b>Methods for considering values and preferences</b>	<ul style="list-style-type: none"> <li>- Solicit topic nominations from public</li> <li>- Review existing research on patients’</li> </ul>

	preferences - Consult patients, caregivers, and advocacy groups regarding barriers to dissemination and implementation
--	---

189

190 For guidelines published in a language other than English, we intended to use Google Translate to  
191 translate the guideline document to facilitate extraction and subsequently ask a native language speaker  
192 to confirm our extractions. We did not, however, identify any eligible guidelines published in a language  
193 other than English.

194 Reviewers resolved discrepancies by discussion, and, if necessary, by adjudication with a third reviewer.

### 195 ***Data synthesis and analysis***

196 Descriptive statistics summarize guideline characteristics, methods, and consideration of values &  
197 preferences. We used content analysis to map the steps in which values and preferences were  
198 considered in guideline development, the purpose for considering values and preferences, and methods  
199 for considering values and preferences to the categories in the Armstrong framework (18).

200 We anticipated that consideration of values and preferences across guidelines may differ according to  
201 the time at which they were published, the topics they address, the jurisdiction of the guideline (high  
202 income versus low/middle income countries), the publishing organization, and whether the guideline  
203 used GRADE methods (52). Hence, we also interpret results considering these characteristics.

## 204 **Results**

### 205 ***Search results***

206 We reviewed 617 guidelines for eligibility, of which 129 proved eligible. Figure 2 presents the selection  
207 of guidelines. Supplement 1 lists included guidelines and Supplement 2 lists the excluded guidelines and  
208 reasons for their exclusion.

### 209 ***Guideline characteristics***

210 Of 129 included guidelines, 73 (56.6%) were published by international organizations, 43 (33.3%) by  
211 national organizations, and 14 (10.9%) by professional societies and associations. We included  
212 guidelines from a total of 25 unique government and non-government organizations. Forty (31%)  
213 guidelines were published in 2020, 48 (37.2%) in 2021, 33 (25.6%) in 2022 and 8 (6.2%) in 2023. Nearly  
214 all guidelines targeted high-income countries or regions (96.9%), typically in North America or Europe.  
215 Guidelines seldom disclosed funding (24; 18.6%) or conflicts of interest (35; 27.1%). Five (3.9%)  
216 guidelines were updates of previously published guidelines.

217 Less than one in 10 guidelines used GRADE to evaluate the certainty of evidence (52). An almost equal  
218 proportion used GRADE evidence-to-decision frameworks to formulate recommendations (10).

219 Guidelines addressed a range of topics, with the most common topics being vaccination and vaccine  
220 prioritization (36; 27.9%), general public health measures (34; 26.4%), and infection control &  
221 prevention (18; 14%). Most guidelines included recommendations that targeted community-dwelling



222 people (42; 32.6%) or were intended to be used by public health practitioners and other decision-  
223 makers (59; 45.7%).

#### 224 **Values and preferences**

225 Of 129 eligible guidelines, 26 (20.2%) considered values and preferences. Seventeen of these guidelines  
226 (65.4%) were published by the WHO, 7 (26.9%) by the CDC, and 1 (3.8%) by the American College of  
227 Obstetricians and Gynecologists. Six (23.1%) of the guidelines were iterations of the WHO living  
228 guideline on infection prevention and control (53-58). None of the guidelines were published in 2020, 8  
229 (30.8%) were published in 2021, 13 (50%) in 2022, and four (15.4%) in 2023. Nearly all guidelines (22;  
230 84.6%) that considered values and preferences also used GRADE methods to evaluate the certainty of  
231 evidence and to move from evidence to recommendations. Guidelines addressed either vaccination and  
232 vaccine prioritization (16; 61.5%), masking in the community (6; 23.1%), or school & education (2; 7.7%).

233 Table 2 describes the consideration of values and preferences in guidelines and table 3 describes the  
234 guidelines that considered values and preferences. Among guidelines that considered values and  
235 preferences, all did so to develop recommendations. Half of these guidelines also recommended for  
236 consideration of values and preferences in the implementation of recommendations (11; 42.3%). None  
237 of the guidelines considered values in preferences in other steps of the guideline development process,  
238 such as nominating or prioritizing topic, drafting recommendations, or disseminating or endorsing the  
239 guideline.

240 The purpose for considering values and preferences was most often to assess the acceptability of  
241 recommendations (23; 88.5%) or to weigh anticipated benefits and harms of alternative courses of  
242 action (15; 57.7%). None of the guidelines reported considering values and preferences for other  
243 purposes, like developing simple language summaries of the recommendations.

244 Most guidelines considered values and preferences by consulting published survey research (24; 92.3%).  
245 These guidelines did not report identifying this published research using systematic review methods.  
246 None of the guidelines performed de novo research or provided opportunity for public comment.  
247 Supplement 3 lists the studies referenced by guidelines as evidence of values and preferences.

248 Less than a quarter of guidelines (6; 23.1%) reported engaging lay persons as part of the guideline  
249 development group. Among guidelines that reported engaging lay persons as part of the guideline  
250 development group, none described the number of lay people consulted or their demographic  
251 characteristics (e.g., age, sex, equity deserving characteristics).

252 A minority of guideline development groups (6; 23.1%) reported making assumptions about public  
253 values and preferences. A minority of guidelines (5; 19.2%) reported consulting with professional  
254 associations about values and preferences.

255 Among guidelines that were updated throughout the course of the pandemic, we did not identify any  
256 guidelines in which values and preferences were first not considered but were later incorporated in  
257 subsequent updates.

- 258 None of the guidelines reflected on lessons learned or the advantages or disadvantages of considering  
259 public values and preferences or evaluated the quality or impact of public engagement.  
260 Box 3 describes examples of ways in which guidelines considered values and preferences.

**Box 3: Examples of ways in which values & preferences informed recommendations**

**Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline (57)**

A guideline by the WHO addressed infection prevention and control interventions (57). The guideline was initially published in 2021, and updated five times (53-58). The guideline made recommendations regarding masking by children and adults in the community and in healthcare settings. For the purposes of this study, we focused on recommendations for community settings.

The guideline used GRADE evidence-to-decision frameworks to formulate recommendations, which involves consideration of the magnitude of benefits and harms, values and preferences, resources, equity, feasibility, and acceptability.

For children under five in the community, the guideline made a conditional recommendation against masks. The guideline reports that recommendations addressing mask use in children were informed by consultations with the United Nations Children's Fund (UNICEF), the International Pediatric Association (IPA), and pediatric health professionals from different geographical regions, regarding children's experiences with masks. It can be assumed that these consultations informed considerations of values and preferences.

In considering values and preferences, the guideline development group noted that there is substantial variability. The guideline did not cite any published studies supporting judgments about values and preferences nor did it describe any de novo studies performed by the guideline development group to inform recommendations. The guideline development group also noted that there is a lack of evidence as to the acceptability of mask use for children in this age group. The guideline cited two studies supporting the acceptability of masking in children. The first study described adherence to masking in pre-K, kindergarten, first, or second grades in Atlanta (59). The second study evaluated mothers' perceptions of masking in children in Nigeria (60).

The guideline made a strong recommendation for mask use for adults in the community in crowded spaces, following a recent exposure, when sharing a space with a person who displays signs or symptoms of COVID-19, and for people at high risk of severe COVID-19 complications.

For this recommendation, values and preferences were informed by collective input and experience of the guideline development group, which comprised members (including laypersons in the community, clinicians, and policymakers) who represented all WHO regions and ranged from low to high-income countries, supplemented by key studies suggested by guideline development group members when available. The guideline did not describe the number of laypersons involved nor their demographic characteristics. The guideline development group assumed that there would be a general preference towards mask use in the community, though values and preferences are likely to vary, and those at higher risk of COVID-19 complications might perceive the benefits of mask use to

be greater compared to other individuals.

The guideline development group also considered acceptability of masks and noted that members of the public may not deem mask use as an acceptable public health intervention. The guideline group cited three studies to support their judgment (61-63), one of which addressed socio-behavioral factors that predict adherence to masks (62) and a review of qualitative studies of the social meaning assigned to masking (63).

#### **Recommendations from the WHO Technical Advisory Group on Safe Schooling During the COVID-19 Pandemic (64)**

Another guideline by the WHO addressed schooling during the COVID-19 pandemic (64). The guideline was developed by a WHO Technical Advisory Group that comprised a range of stakeholders, including young people. The guideline made a recommendation to actively involve children and adolescents in decision-making regarding schooling. The guideline, however, did not describe the number of young people, the countries from which they were recruited, their age, and demographic characteristics, and the purpose for which values and preferences were considered.

#### **The CDC Advisory Committee on Immunization Practices (ACIP) Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged $\geq 18$ Years (65)**

A guideline by the CDC Advisory Committee on Immunization Practices (ACIP) makes a recommendation regarding the Moderna COVID-19 Vaccine (65). The guideline uses GRADE evidence-to-decision framework (called the evidence-to-recommendation framework) to arrive at a recommendation. The evidence-to-decision framework includes consideration of values and preferences, as well as other factors like feasibility, resource use, and equity. In considering values and preferences, the guideline references existing survey research that suggests that most US adults intend to be vaccinated against COVID-19 and vaccination rates following the approval of the Pfizer-BioNTech COVID-19 vaccine. The guideline development group noted variability and uncertainty in how all populations value the vaccine. For example, most surveys used convenience sampling, had limited representation of minority populations, and low or unknown response rates.

## 261 **Discussion**

### 262 ***Main findings***

263 Our systematic review of 129 COVID-19 public health guidelines found that they seldom considered  
264 values and preferences. Among the few guidelines that considered values and preferences, we found  
265 limitations in how they were considered. For example, none of the included guidelines performed or  
266 referenced systematic reviews of values and preferences. Instead, they referenced select research  
267 publications without a description of how the studies were identified. Failure to perform systematic  
268 reviews risks cherry-picking studies based on their findings. Some guideline development groups made  
269 assumptions about the public's values and preferences. This approach, though practical, may be  
270 suboptimal because the general public likely weighs pandemic policy decisions differently than  
271 professionals (31).

272 The pandemic forced guideline developers to produce guidelines quickly under circumstances that did  
273 not allow for typical guideline development procedures such as in-person meetings or travel. While the  
274 pressures of the pandemic may account for the suboptimal consideration of values and preferences, we  
275 show that even guidelines produced three years into the pandemic, when most of these challenges were  
276 mitigated and circumstances had normalized, did not consider values and preferences. Further, none of  
277 the guidelines explicitly acknowledged lack of or inadequate consideration of values and preferences,  
278 engagement of the public, or the use of pragmatic approaches as limitations.

279 Thus, other factors are more likely to explain the suboptimal consideration of values and preferences.  
280 Until recently, there has been limited consensus on the ideal approaches to involve laypersons in  
281 guideline development (11, 22, 66). For example, while methodological handbooks strongly encourage  
282 consideration of values and preferences, they contain little practical guidance (12, 21, 22). Hence, even  
283 if guideline developers may have wished to incorporate values and preferences, they may have been  
284 uncertain about how to do so effectively. Adding to this already complex process is evidence that values  
285 and preferences related to COVID-19 recommendations varied widely across regions and age groups and  
286 changed during the pandemic (67-70). Such challenges might have discouraged guideline developers  
287 from giving priority to this issue.

288 The omission of values and preferences could also be attributed to guideline developers' limited  
289 familiarity with established standards for developing trustworthy guidelines. This is further evidenced by  
290 additional methodological oversights in guidelines, such as the failure to disclose the conflicts of  
291 interests of the guideline development group. Moreover, a recent study also showed that few COVID-19  
292 recommendations considered issues related to health equity—an aspect increasingly recognized as an  
293 important component of guideline development (71). Such patterns suggest that guideline developers  
294 that did not consider values and preferences might not be fully aware of established standards for  
295 trustworthy guideline development.

#### 296 ***Relation to previous research***

297 This review is the first to systematically examine how COVID-19 public health guidelines considered  
298 public values and preferences. Prior research on COVID-19 guideline quality has mainly focused on  
299 clinical practice guidelines (e.g., guidelines that advise healthcare providers on the treatment of patients  
300 with COVID-19) (29, 31, 72). Previous evidence on public engagement during COVID-19 has typically  
301 been in the form of anecdotal evidence and case studies (29, 31, 72). For example, the Scottish  
302 government hosted an online public discussion about people's ideas and concerns around lockdown,  
303 which generated 18,000 comments from citizens (73). In the Netherlands, 30,000 citizens advised the  
304 government on relaxing lockdown measures (31). Our work systematically evaluates how and to what  
305 extent COVID-19 guidelines accounted for public values and preferences.

#### 306 ***Strengths and limitation***

307 The strengths of this review include our systematic search for COVID-19 public health guidelines and  
308 rigorous collection of data on values and preferences by two reviewers independently using an  
309 established framework for consideration of values and preferences.

310 Although we attempted to provide a comprehensive overview of all COVID-19 public health guidelines,  
311 there remains a possibility that some eligible guidelines were excluded. We used the eCOVID-19 RecMap  
312 platform to identify guidelines—originally designed to reduce the time and resources organizations  
313 would need to invest to develop de novo guidelines and to facilitate guideline adaptation (42, 44, 45).  
314 Moreover, the eCOVID19 RecMap appears to favor guidelines from the most influential organizations  
315 that likely have the highest standards for developing guidelines (e.g., WHO, CDC). Consequently, our  
316 sample likely includes an overrepresentation of guidelines that consider values and preferences.

317 Likewise, although we used a broad definition and operationalization of values and preferences, it is  
318 possible that our definition and framework may not have captured guideline developers' considerations  
319 of values and preferences (18).

320 To identify eligible guidelines, reviewers worked independently and in duplicate to screen all  
321 recommendations catalogued on the eCOVID-19 RecMap. Any guideline that contained at minimum one  
322 eligible recommendation was included. Given the length and complexity of guideline documents, it is  
323 possible that we may have missed guidelines that included eligible recommendations.

324 For feasibility, we restricted eligibility to national and international guidelines and excluded regional  
325 guidelines. It is possible for national and international guidelines to be adapted into regional settings  
326 during which local values and preferences may be considered.

327 Guidelines are sometimes updated as new evidence emerges and a single guideline may include several  
328 versions. We intended to include all versions of guidelines to study how consideration of values and  
329 preferences may have evolved during the pandemic. It is possible that some organizations removed  
330 access to outdated guidelines or replaced outdated guidelines on webpages, precluding their inclusion  
331 in our study.

332 It is possible that guidelines considered values and preferences but did not report on such  
333 considerations. For example, a survey of guideline developers showed that organizations often implicitly  
334 rather than explicitly consider values and preferences (66). Nevertheless, failure to explicitly report  
335 consideration of values and preferences reduces the guideline's transparency and leaves readers unable  
336 to evaluate its credibility.

337 For select recommendations, such as good practice statements that summarize recommendations  
338 where the alternative would be absurd (e.g., a recommendation for surgeons to forego handwashing  
339 before a surgical procedure), values and preferences are unlikely to be consequential (44, 45). We,  
340 however, restricted our study to guidelines that addressed recommendations that require consideration  
341 of values and preferences. For example, recommendations addressing isolation, lockdowns, and other  
342 infection control measures necessitate weighing immediate benefits of controlling the virus against  
343 broader health and socioeconomic consequences (47, 48).

344 We did not review documents from guideline producing organizations outlining their typical standards  
345 and methods for developing guidelines. We anticipated that these organizations may have diverged  
346 from typical practices due to the unique context presented by the COVID-19 pandemic. Likewise,

347 inferences on how recommendations might have differed if values and preferences were considered  
348 were beyond the scope of this study.

### 349 ***Implications***

350 As the pandemic evolves from an acute threat to a long-term public health issue, now is a critical time to  
351 reflect and learn from our response to inform future emergency preparedness efforts. While the COVID-  
352 19 pandemic was unprecedented, we anticipate other health emergencies that will also benefit from  
353 guidelines that are aligned with societal values.

354 Our investigation revealed that few COVID-19 public health guidelines considered values and  
355 preferences, which may have contributed to unpopular pandemic policies and led to an erosion of trust  
356 in public health (35-38, 74-77). This erosion of trust may present a challenge for managing future crises,  
357 which may again require cohesive and coordinated efforts from the public.

358 We acknowledge that guideline developers and decision-makers may be reluctant to consider values  
359 and preferences in favor of relying only on scientific evidence. Considering values and preferences  
360 respects the rights of citizens to participate in health decision-making, aligns guidelines with the needs  
361 and priorities of the communities they are intended to serve, ensures recommendations are logistically  
362 feasible and acceptable, and improves support for the recommendations (13, 14). Formulating  
363 recommendations will invariably involve inherent value judgements—alternative courses of action are  
364 almost always accompanied by both benefits and harms and value judgments are necessary to  
365 determine whether benefits of a particular course of action outweigh harms or vice versa. For these  
366 reasons, all guideline producing organizations and organizations that establish standards for developing  
367 guidelines require consideration of values and preferences (2, 3, 10, 16, 78).

368 Our results suggest that guideline developers may not be aware of standards that necessitate  
369 consideration of values and preferences. Therefore, we recommend future efforts focus on improving  
370 guideline developers' understanding of the importance of values and preferences in formulating  
371 recommendations.

372 Future research could also address guideline developers' experiences considering values and  
373 preferences in COVID-19 guidelines. Surveys and interviews with guideline developers can provide  
374 insights on facilitators and barriers to public engagement during the pandemic and identify efficient  
375 methods for considering values and preferences in health emergencies and crisis situations. Such  
376 research will ensure that future health crises are met with public health guidelines that are aligned with  
377 core societal values.

### 378 **Conclusion**

379 We reviewed a sample of COVID-19 public health guidelines to capture and characterize whether and  
380 how they considered public values and preferences. We found few COVID-19 public health guidelines to  
381 consider public values and preferences. Where values and preferences were considered, it was using  
382 suboptimal methods. Disregard for values and preferences might have contributed to divisive COVID-19  
383 policies. While the COVID-19 pandemic was unprecedented, we anticipate other health emergencies  
384 that will also benefit from guidelines that are aligned with societal values. We recommend future

385 research identify efficient methods for considering values and preferences in health emergencies and  
386 crisis situations.

<b>Table 1: Guideline characteristics</b>			
<b>Publisher</b>		<b>Topic</b>	
Government organization	43 (33.3%)	Cultural practices in the context of COVID-19	2 (1.6%)
Professional association	14 (10.9%)	School and education	4 (3.1%)
International agency	73 (56.6%)	Lockdowns and isolation	5 (3.9%)
<b>Region</b>		Masking	10 (7.8%)
North America	44 (34.1%)	Vaccination & vaccine prioritization	36 (27.9%)
Europe	25 (19.4%)	General public health measures	34 (26.4%)
Asia	4 (3.1%)	Operation of healthcare facilities related to visitation	1 (0.8%)
Africa	0 (0%)	Contact tracing	6 (4.7%)
South America	0 (0%)	Infection control & prevention	18 (14.0%)
Oceania	1 (0.8%)	Travel	5 (3.9%)
International	55 (42.6%)	Testing for COVID-19	2 (1.6%)
<b>Date of publication</b>		Public health surveillance and response plan	6 (4.7%)
January to June 2020	23 (17.8%)	<b>Target users</b>	
July to December 2020	17 (13.2%)	Children	13 (10.1%)
January to June 2021	24 (18.6%)	Elderly	1 (0.8%)
July to December 2021	24 (18.6%)	Community-dwelling people	42 (32.6%)
January to June 2022	24 (18.6%)	Mothers and infants	2 (1.6%)
July to December 2022	9 (7%)	Refugees and asylum seekers	7 (5.4%)
January to June 2023	8 (6.2%)	Public health professionals and other decision-makers	59 (45.7%)
<b>Funding</b>		Staff	5 (3.9%)
Not reported	105 (81.4%)	<b>Setting</b>	
No funding	6 (4.7%)	Community	104 (80.6%)
Governmental support	6 (4.7%)	School/university/college	11 (8.5%)
Institutional support	15 (11.6%)	Healthcare facilities	8 (6.2%)
Private not-for-profit foundation	1 (0.8%)	Long term care facilities	2 (1.6%)
<b>Disclosure of conflicts of interest</b>		Detention center/homeless service sites	4 (3.1%)
Not reported	89 (69%)	<b>GRADE methods</b>	
None	23 (17.8%)	GRADE to evaluate the certainty of evidence	24 (18.6%)



Disclosed potential interests for one or more members involved with the development of the guideline	17 (13.2%)	GRADE to move from evidence to recommendations	23 (17.8%)
<b>Methods to manage conflicts of interest</b>		Did not use GRADE	104 (80.6%)
Not reported	94 (72.9%)		
Members of the guideline development group disclosed conflicts and none of the members of the guideline development group were deemed to have relevant conflicts	16 (12.4%)		
Members of the guideline development group disclosed conflicts and a member of the publishing organization reviewed and managed conflicts of interest	2 (1.6%)		
Members of the guideline development group disclosed conflicts and those with conflicts recused from formulating recommendation	14 (10.9%)		

**Table 2: Description of the steps, purpose, and methods by which guidelines considered values and preferences**

<b>Step of the guideline development process in which values and preferences were considered</b>	
Developing recommendations	26 (100%)
Recommend for consideration of values and preferences in implementation of recommendations	11 (42.3%)
<b>Purpose for considering of values and preferences</b>	
Considering acceptability of recommendations	23 (88.5%)
Weighing benefits and harms	15 (57.7%)
Identifying barriers to implementation and possible solutions	1 (3.8%)
Not reported	1 (3.8%)
<b>Methods to consider values and preferences</b>	
Referenced existing survey research on values and preferences	24 (92.3%)
Referenced existing interview research on values and preferences	1 (3.8%)
Engaged lay persons as part of guideline development group	6 (23.1%)
Guideline development group made assumptions about values and preferences	6 (23.1%)
Consulted with professional associations	5 (19.2%)
Not reported	1 (3.8%)

**Table 3: Description of guidelines that considered values and preferences**

Guideline title	Publisher	Latest update	Country	Topic	Consideration of values and preferences		
					Step	Purpose	Methods
<b>Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022 (79)</b>	CDC	2022	US	Vaccination & vaccine prioritization	Developing recommendations	Acceptability	Referenced existing research on patients' preferences
<b>COVID-19 immunization in refugees and migrants: principles and key considerations: interim guidance, 31 August 2021 (80)</b>	WHO	2021	International	Vaccination & vaccine prioritization	Developing recommendations	Identify barriers to implementation and possible solutions	Referenced existing research on patients' preferences
<b>COVID-19 Vaccination Considerations for Obstetric–Gynecologic Care (81)</b>	American College of Obstetricians and Gynecologists	2023	United States	Vaccination & vaccine prioritization	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms	NR
<b>Guideline WHO Infection Prevention and Control COVID-19 Living Guideline - Mask use in community settings (58)</b>	WHO	2021	International	Masking	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences; Asked guideline development group to make assumptions about preferences;
<b>Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline, 10 August 2023 (55)</b>	WHO	2023	International	Masking	Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences; Asked guideline development group to make assumptions about preferences; Consulted authoritative professional associations; Directly engaged lay persons on guideline development group
<b>Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline, 13 January 2023 (53)</b>	WHO	2023	International	Masking	Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences; Asked guideline development group to make assumptions about preferences; Consulted authoritative professional associations; Directly engaged lay persons on guideline development group
<b>Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline, 25 April 2022: updated chapter: mask use, part 1:</b>	WHO	2022	International	Masking	Developing recommendations	Weighing benefits and harms;	Referenced existing research on patients' preferences; Asked guideline development group to make assumptions about preferences;


<b>health care settings (54)</b>						Acceptability	Consulted authoritative professional associations; Directly engaged lay persons on guideline development group
<b>Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline, 7 March 2022 (56)</b>	WHO	2022	International	Masking	Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences; Asked guideline development group to make assumptions about preferences; Consulted authoritative professional associations; Directly engaged lay persons on guideline development group
<b>Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline, 9 October 2023 (57)</b>	WHO	2023	International	Masking	Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences; Asked guideline development group to make assumptions about preferences; Consulted authoritative professional associations; Directly engaged lay persons on guideline development group
<b>Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years — United States, July 2022 (82)</b>	CDC	2022	US	Vaccination & vaccine prioritization	Developing recommendations	Acceptability	Referenced existing research on patients' preferences
<b>Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine (83)</b>	WHO	2022	International	Vaccination & vaccine prioritization	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences
<b>Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19: interim guidance, first issued 3 November 2021, updated 15 March 2022 (84)</b>	WHO	2022	International	Vaccination & vaccine prioritization	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences
<b>Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) (85)</b>	WHO	2022	International	Vaccination & vaccine prioritization	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences
<b>Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotech Group (CNBG), Sinopharm (86)</b>	WHO	2021	International	Vaccination & vaccine prioritization	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences
<b>Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by</b>	WHO	2022	International	Vaccination & vaccine	Recommend for consideration of values & preferences in	Weighing benefits and	Referenced existing research on patients' preferences

<b>Sinovac: interim guidance (87)</b>				prioritization	implementation of recommendations; Developing recommendations	harms; Acceptability	
<b>Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19: interim guidance (88)</b>	WHO	2022	International	Vaccination & vaccine prioritization	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences
<b>Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19: interim guidance, 20 December 2021 "Update coming soon" (89)</b>	WHO	2022	International	Vaccination & vaccine prioritization	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences
<b>Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing (90)</b>	WHO	2022	International	Vaccination & vaccine prioritization	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Weighing benefits and harms; Acceptability	Referenced existing research on patients' preferences
<b>Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022 (91)</b>	CDC	2022	US	Vaccination & vaccine prioritization	Developing recommendations	Acceptability	Referenced existing research on patients' preferences
<b>Recommendations from the WHO Technical Advisory Group on Safe Schooling During the COVID-19 Pandemic: revised version following the eighth TAG meeting, 20 January 2022 (64)</b>	WHO	2022	International	School & education	Developing recommendations	NR	Directly engage lay persons as part of guideline development group
<b>Schooling during COVID-19: recommendations from the European Technical Advisory Group for schooling during COVID-19, June 2021 (92)</b>	WHO	2021	International	School & education	Recommend for consideration of values & preferences in implementation of recommendations; Developing recommendations	Acceptability	Referenced existing research on patients' preferences
<b>The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine (65)</b>	CDC	2022	US	Vaccination & vaccine prioritization	Developing recommendations	Acceptability	Referenced existing research on patients' preferences
<b>The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years—United States, May 2021 (93)</b>	CDC	2021	US	Vaccination & vaccine prioritization	Developing recommendations	Acceptability	Referenced existing research on patients' preferences
<b>The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged</b>	CDC	2021	US	Vaccination & vaccine prioritization	Developing recommendations	Acceptability	Referenced existing research on patients' preferences

<b>5–11 Years (94)</b>								
<b>The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021 (95)</b>	CDC	2021	US	Vaccination & vaccine prioritization	Developing recommendations	Acceptability	Referenced existing research on patients' preferences	
<b>Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2021 (96)</b>	CDC	2021	US	Vaccination & vaccine prioritization	Developing recommendations	Acceptability	Referenced existing research on patients' preferences	
CDC: Centers for Disease Control and Prevention WHO: World Health Organization								

388


389 **Figure 1: Overview of methods and findings**



390

391 **Caption:** We searched the eCOVID19 RecMap platform—a comprehensive international catalog of COVID-19 guidelines—for COVID-19 public  
 392 health guidelines containing one or more recommendations addressing vaccination, masking, isolation, lockdowns, travel restrictions, contact  
 393 tracing, infection surveillance, and school closures. Reviewers worked independently and in duplicate to assess guidelines for eligibility. From  
 394 eligible guidelines, reviewers again worked independently and duplicate to collect information on whether and how guidelines considered public  
 395 values and preferences. Reviewers used a previously established framework by Armstrong and colleagues classify the steps in guideline  
 396 development in which values and preferences were considered, the purpose for which values and preferences were considered, and the  
 397 methods used to consider values and preferences.

398 **Figure 2: Selection of guidelines**



399  
400

401 **Caption:** We searched the eCOVID19 RecMap platform—a comprehensive international catalog of  
402 COVID-19 guidelines—for COVID-19 public health guidelines containing one or more recommendations  
403 addressing vaccination, masking, isolation, lockdowns, travel restrictions, contact tracing, infection  
404 surveillance, and school closures. We supplemented our search by reviewing webpages of national and  
405 international guideline producing organizations (i.e., WHO, US CDC, and European Centers for Disease  
406 Control) and reviewing the references of the included guidelines, by which we identified five additional  
407 guidelines. Reviewers worked independently and in duplicate to assess guidelines for eligibility.  
408 Ultimately, 129 guidelines met eligibility and were included in this study.

409



## 410 References

- 411 1. National Institute for Health and Clinical Excellence. The Guidelines Manual. London: National  
412 Institute for Health and Clinical Excellence; 2007.
- 413 2. Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice G. In:  
414 Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, editors. Clinical Practice Guidelines  
415 We Can Trust. Washington (DC): National Academies Press (US); 2011.
- 416 3. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing  
417 guideline development, reporting and evaluation in health care. *Cmaj*. 2010;182(18):E839-42.
- 418 4. Qaseem A, Forland F, Macbeth F, Ollenschläger G, Phillips S, van der Wees P. Guidelines  
419 International Network: toward international standards for clinical practice guidelines. *Ann Intern Med*.  
420 2012;156(7):525-31.
- 421 5. Schünemann HJ, Wiercioch W, Etzeandía I, Falavigna M, Santesso N, Mustafa R, et al. Guidelines  
422 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. *Cmaj*.  
423 2014;186(3):E123-42.
- 424 6. Guyatt GH, Sinclair J, Cook DJ, Glasziou P, for the Evidence-Based Medicine Working Group and  
425 the Cochrane Applicability Methods Working Group. Users' guides to the medical literature: XVI. How to  
426 use a treatment recommendation. *JAMA* 1999;281:1836e43.
- 427 7. Guyatt GH, Haynes RB, Jaeschke RZ, Cook DJ, Green L, Naylor CD, et al. Users' guides to the  
428 medical literature: XXV. Evidence-based medicine: principles for applying the users' guides to patient  
429 care. *JAMA* 2000;284:1290e6.
- 430 8. Bouvy JC, Cowie L, Lovett R, Morrison D, Livingstone H, Crabb N. Use of patient preference  
431 studies in HTA decision making: a NICE perspective. *Patient* 2020;13:145e9.
- 432 9. Cochrane. Cochrane consumer engagement and involvement framework to 2027.  
433 [https://consumers.cochrane.org/sites/consumers.cochrane.org/files/uploads/inline-](https://consumers.cochrane.org/sites/consumers.cochrane.org/files/uploads/inline-files/Cochrane%20consumer%20engagement%20and%20involvement%20framework%20to%202027_1.pdf)  
434 [files/Cochrane%20consumer%20engagement%20and%20involvement%20framework%20to%202027\\_1.pdf](https://consumers.cochrane.org/sites/consumers.cochrane.org/files/uploads/inline-files/Cochrane%20consumer%20engagement%20and%20involvement%20framework%20to%202027_1.pdf).
- 435 10. Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al.  
436 GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well  
437 informed healthcare choices. 1: Introduction. *BMJ*. 2016;353:i2016.
- 438 11. Zeng L, Helsing LM, Bretthauer M, Agoritsas T, Vandvik PO, Mustafa RA, et al. A novel  
439 framework for incorporating patient values and preferences in making guideline recommendations:  
440 guideline panel surveys. *J Clin Epidemiol*. 2023.
- 441 12. Légaré F, Boivin A, van der Weijden T, Pakenham C, Burgers J, Légaré J, et al. Patient and public  
442 involvement in clinical practice guidelines: a knowledge synthesis of existing programs. *Med Decis*  
443 *Making*. 2011;31(6):E45-74.
- 444 13. Sacristán JA, Aguarón A, Avendaño-Solá C, Garrido P, Carrión J, Gutiérrez A, et al. Patient  
445 involvement in clinical research: why, when, and how. *Patient Prefer Adherence*. 2016;10:631-40.
- 446 14. Armstrong MJ, Mullins CD, Gronseth GS, Gagliardi AR. Impact of patient involvement on clinical  
447 practice guideline development: a parallel group study. *Implementation Science*. 2018;13(1):55.
- 448 15. Schünemann HJ, Wiercioch W, Brozek J, Etzeandía-Ikobaltzeta I, Mustafa RA, Manja V, et al.  
449 GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of  
450 trustworthy recommendations: GRADE-ADOLOPMENT. *J Clin Epidemiol*. 2017;81:101-10.
- 451 16. World Health O. WHO handbook for guideline development. 2nd ed. Geneva: World Health  
452 Organization; 2014 2014.
- 453 17. Biddle MSY, Gibson A, Evans D. Attitudes and approaches to patient and public involvement  
454 across Europe: A systematic review. *Health Soc Care Community*. 2021;29(1):18-27.
- 455

- 456 18. Armstrong MJ, Rueda JD, Gronseth GS, Mullins CD. Framework for enhancing clinical practice  
457 guidelines through continuous patient engagement. *Health Expect*. 2017;20(1):3-10.
- 458 19. Zhang Y, Coello PA, Brožek J, Wiercioch W, Etxeandia-Ikobaltzeta I, Akl EA, et al. Using patient  
459 values and preferences to inform the importance of health outcomes in practice guideline development  
460 following the GRADE approach. *Health Qual Life Outcomes*. 2017;15(1):52.
- 461 20. Kim C, Armstrong MJ, Berta WB, Gagliardi AR. How to identify, incorporate and report patient  
462 preferences in clinical guidelines: A scoping review. *Health Expect*. 2020;23(5):1028-36.
- 463 21. Kim C, Berta WB, Gagliardi AR. Exploring approaches to identify, incorporate and report patient  
464 preferences in clinical guidelines: Qualitative interviews with guideline developers. *Patient Educ Couns*.  
465 2021;104(4):703-8.
- 466 22. Selva A, Sanabria AJ, Pequeño S, Zhang Y, Solà I, Pardo-Hernandez H, et al. Incorporating  
467 patients' views in guideline development: a systematic review of guidance documents. *Journal of Clinical  
468 Epidemiology*. 2017;88:102-12.
- 469 23. Zhang Y, Alonso-Coello P, Guyatt GH, Yepes-Nuñez JJ, Akl EA, Hazlewood G, et al. GRADE  
470 Guidelines: 19. Assessing the certainty of evidence in the importance of outcomes or values and  
471 preferences-Risk of bias and indirectness. *J Clin Epidemiol*. 2019;111:94-104.
- 472 24. Zhang Y, Coello PA, Guyatt GH, Yepes-Nuñez JJ, Akl EA, Hazlewood G, et al. GRADE guidelines:  
473 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences-  
474 inconsistency, imprecision, and other domains. *J Clin Epidemiol*. 2019;111:83-93.
- 475 25. Zheng Q, Jones FK, Leavitt SV, Ung L, Labrique AB, Peters DH, et al. HIT-COVID, a global database  
476 tracking public health interventions to COVID-19. *Scientific Data*. 2020;7(1):286.
- 477 26. Wang D, Mao Z. A comparative study of public health and social measures of COVID-19  
478 advocated in different countries. *Health Policy*. 2021;125(8):957-71.
- 479 27. Fouda A, Mahmoudi N, Moy N, Paolucci F. The COVID-19 pandemic in Greece, Iceland, New  
480 Zealand, and Singapore: Health policies and lessons learned. *Health Policy and Technology*.  
481 2020;9(4):510-24.
- 482 28. Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. Estimating the effects of  
483 non-pharmaceutical interventions on COVID-19 in Europe. *Nature*. 2020;584(7820):257-61.
- 484 29. Richards T, Scowcroft H. Patient and public involvement in covid-19 policy making. *BMJ*.  
485 2020;370:m2575.
- 486 30. Casassus B. Covid-19: French sidelining of patient associations is a global trend. *Bmj*.  
487 2020;371:m4082.
- 488 31. Mouter N, Hernandez JI, Itten AV. Public participation in crisis policymaking. How 30,000 Dutch  
489 citizens advised their government on relaxing COVID-19 lockdown measures. *PLOS ONE*.  
490 2021;16(5):e0250614.
- 491 32. Dostal JM. Governing Under Pressure: German Policy Making During the Coronavirus Crisis. *Polit  
492 Q*. 2020;91(3):542-52.
- 493 33. Schünemann HJ, Santesso N, Vist GE, Cuello C, Lotfi T, Flottorp S, et al. Using GRADE in situations  
494 of emergencies and urgencies: certainty in evidence and recommendations matters during the COVID-19  
495 pandemic, now more than ever and no matter what. *J Clin Epidemiol*. 2020;127:202-7.
- 496 34. Schoch-Spana M, Franco C, Nuzzo JB, Usenza C. Community engagement: leadership tool for  
497 catastrophic health events. *Biosecur Bioterror*. 2007;5(1):8-25.
- 498 35. Dyer O. Covid-19: Ottawa declares emergency as truckers' protest continues. *Bmj*.  
499 2022;376:o352.
- 500 36. Paterlini M. Covid-19: Italy sees protests against mandatory health passports for workplaces.  
501 *Bmj*. 2021;375:n2575.
- 502 37. Druml C, Czech H. A pandemic is no private matter: the COVID-19 vaccine mandate in Austria.  
503 *Lancet Respir Med*. 2022;10(4):322-4.

- 504 38. Ward JK, Gauna F, Gagneux-Brunon A, Botelho-Nevers E, Cracowski JL, Khouri C, et al. The  
505 French health pass holds lessons for mandatory COVID-19 vaccination. *Nat Med.* 2022;28(2):232-5.
- 506 39. Sleath B, Carpenter DM, Slota C, Williams D, Tudor G, Yeatts K, et al. Communication during  
507 pediatric asthma visits and self-reported asthma medication adherence. *Pediatrics.* 2012;130(4):627-33.
- 508 40. Cronin RM, Mayo-Gamble TL, Stimpson SJ, Badawy SM, Crosby LE, Byrd J, et al. Adapting medical  
509 guidelines to be patient-centered using a patient-driven process for individuals with sickle cell disease  
510 and their caregivers. *BMC Hematol.* 2018;18:12.
- 511 41. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020  
512 statement: an updated guideline for reporting systematic reviews. *Bmj.* 2021;372:n71.
- 513 42. Nasir ZH, Mertz D, Nieuwlaat R, Santesso N, Lotfi T, Motilall A, et al. An evaluation of the COVID-  
514 19 recommendation map identified diverging clinical and public health guidance. *J Clin Epidemiol.*  
515 2022;147:83-94.
- 516 43. Lotfi T, Stevens A, Akl EA, Falavigna M, Kredo T, Mathew JL, et al. Getting trustworthy guidelines  
517 into the hands of decision-makers and supporting their consideration of contextual factors for  
518 implementation globally: recommendation mapping of COVID-19 guidelines. *J Clin Epidemiol.*  
519 2021;135:182-6.
- 520 44. Dewidar O, Lotfi T, Langendam MW, Parmelli E, Saz Parkinson Z, Solo K, et al. Good or best  
521 practice statements: proposal for the operationalisation and implementation of GRADE guidance. *BMJ*  
522 *Evid Based Med.* 2023;28(3):189-96.
- 523 45. Guyatt GH, Alonso-Coello P, Schünemann HJ, Djulbegovic B, Nothacker M, Lange S, et al.  
524 Guideline panels should seldom make good practice statements: guidance from the GRADE Working  
525 Group. *J Clin Epidemiol.* 2016;80:3-7.
- 526 46. Bardosh K, Krug A, Jamrozik E, Lemmens T, Keshavjee S, Prasad V, et al. COVID-19 vaccine  
527 boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at  
528 universities. *J Med Ethics.* 2022.
- 529 47. Allen DW. Covid-19 Lockdown Cost/Benefits: A Critical Assessment of the Literature.  
530 *International Journal of the Economics of Business.* 2022;29(1):1-32.
- 531 48. Miles DK, Stedman M, Heald AH. "Stay at Home, Protect the National Health Service, Save  
532 Lives": A cost benefit analysis of the lockdown in the United Kingdom. *Int J Clin Pract.*  
533 2021;75(3):e13674.
- 534 49. Silverman M, Sibbald R, Stranges S. Ethics of COVID-19-related school closures. *Can J Public*  
535 *Health.* 2020;111(4):462-5.
- 536 50. Christakis DA, Van Cleve W, Zimmerman FJ. Estimation of US Children's Educational Attainment  
537 and Years of Life Lost Associated With Primary School Closures During the Coronavirus Disease 2019  
538 Pandemic. *JAMA Netw Open.* 2020;3(11):e2028786.
- 539 51. Ienca M, Vayena E. On the responsible use of digital data to tackle the COVID-19 pandemic. *Nat*  
540 *Med.* 2020;26(4):463-4.
- 541 52. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging  
542 consensus on rating quality of evidence and strength of recommendations. *Bmj.* 2008;336(7650):924-6.
- 543 53. World Health Organization (WHO) Infection prevention and control in the context of coronavirus  
544 disease (COVID-19): a living guideline, 13 January 2023. January 2023.
- 545 54. World Health Organization (WHO) Infection prevention and control in the context of coronavirus  
546 disease (COVID-19): a living guideline, 25 April 2022: updated chapter: mask use, part 1: health care  
547 settings. April 2022.
- 548 55. World Health Organization (WHO) Infection prevention and control in the context of coronavirus  
549 disease (COVID-19): a living guideline, 10 August 2023. August 2023.
- 550 56. World Health Organization (WHO) Infection prevention and control in the context of coronavirus  
551 disease (COVID-19): a living guideline, 7 March 2022. March 2022.

- 552 57. World Health Organization (WHO) Infection prevention and control in the context of coronavirus  
553 disease (COVID-19): a living guideline, 9 October 2023. October 2023
- 554 58. World Health Organization (WHO) Guideline WHO Infection Prevention and Control COVID-19  
555 Living Guideline - Mask use in community settings. December 2021.
- 556 59. Mickells GE, Figueroa J, West KW, Wood A, McElhanon BO. Adherence to Masking Requirement  
557 During the COVID-19 Pandemic by Early Elementary School Children. *J Sch Health*. 2021;91(7):555-61.
- 558 60. Aronu AE, Chinawa JM, Nduagubam OC, Ossai EN, Chinawa AT, Igwe WC. Maternal perception  
559 of masking in children as a preventive strategy for COVID-19 in Nigeria: A multicentre study. *PLoS One*.  
560 2020;15(11):e0242650.
- 561 61. Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, et al. A global panel database of  
562 pandemic policies (Oxford COVID-19 Government Response Tracker). *Nat Hum Behav*. 2021;5(4):529-38.
- 563 62. Face masks and coverings for the general public: Behavioural knowledge, effectiveness of cloth  
564 coverings and public messaging. The Royal Society. 2020.
- 565 63. Tsang PM, Prost A. Boundaries of solidarity: a meta-ethnography of mask use during past  
566 epidemics to inform SARS-CoV-2 suppression. *BMJ Glob Health*. 2021;6(1).
- 567 64. World Health Organization (WHO) Recommendations from the WHO Technical Advisory Group  
568 on Safe Schooling During the COVID-19 Pandemic: revised version following the eighth TAG meeting, 20  
569 January 2022. January 2022.
- 570 65. Wallace M, Moulia D, Blain AE, Ricketts EK, Minhaj FS, Link-Gelles R, et al. The Advisory  
571 Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in  
572 Adults Aged  $\geq 18$  Years and Considerations for Extended Intervals for Administration of Primary Series  
573 Doses of mRNA COVID-19 Vaccines — United States, February 2022. *Centers for Disease Control and  
574 Prevention (CDC)*. February 2022;71(11):416-21.
- 575 66. Blackwood J, Armstrong MJ, Schaefer C, Graham ID, Knaapen L, Straus SE, et al. How do  
576 guideline developers identify, incorporate and report patient preferences? An international cross-  
577 sectional survey. *BMC Health Serv Res*. 2020;20(1):458.
- 578 67. Levitt EE, Gohari MR, Syan SK, Belisario K, Gillard J, DeJesus J, et al. Public health guideline  
579 compliance and perceived government effectiveness during the COVID-19 pandemic in Canada: Findings  
580 from a longitudinal cohort study. *Lancet Reg Health Am*. 2022;9:100185.
- 581 68. Sabat I, Neumann-Böhme S, Varghese NE, Barros PP, Brouwer W, van Exel J, et al. United but  
582 divided: Policy responses and people's perceptions in the EU during the COVID-19 outbreak. *Health  
583 Policy*. 2020;124(9):909-18.
- 584 69. Moran C, Campbell DJT, Campbell TS, Roach P, Bourassa L, Collins Z, et al. Predictors of attitudes  
585 and adherence to COVID-19 public health guidelines in Western countries: a rapid review of the  
586 emerging literature. *J Public Health (Oxf)*. 2021;43(4):739-53.
- 587 70. Betsch C, Korn L, Felgendreff L, Eitze S, Thaiss H. School opening during the SARS-CoV-2  
588 pandemic: Public acceptance of wearing fabric masks in class. *Public Health Pract (Oxf)*. 2021;2:100115.
- 589 71. Dewidar O, Bondok M, Abdelrazeq L, Aliyeva K, Solo K, Welch V, et al. Equity issues rarely  
590 addressed in the development of COVID-19 formal recommendations and good practice statements: a  
591 cross-sectional study. *J Clin Epidemiol*. 2023;161:116-26.
- 592 72. Tripp L, Vanstone M, Canfield C, Leslie M, Levasseur MA, Panday J, et al. The impact of COVID-19  
593 on patient engagement in the health system: Results from a Pan-Canadian survey of patient, family and  
594 caregiver partners. *Health Expect*. 2022;25(2):744-53.
- 595 73. Webster N. Public discussions on COVID-19 lockdown in Scotland 2020 [Available from:  
596 <https://medium.com/participo/public-discussions-on-covid-19-lockdown-in-scotland-8f34a586c69c>].
- 597 74. Emanuel EJ, Upshur REG, Smith MJ. What Covid Has Taught the World about Ethics. *N Engl J  
598 Med*. 2022;387(17):1542-5.
- 599 75. Parasidis E, Fairchild AL. Closing the Public Health Ethics Gap. *N Engl J Med*. 2022;387(11):961-3.

- 600 76. Jamrozik E. Public health ethics: critiques of the “new normal”. *Monash Bioethics Review*.  
601 2022;40(1):1-16.
- 602 77. Cox, Daniel A., Anthony M. Mills, Ian R. Banks, Kelsey Eyre Hammond, and Kyle Gray.  
603 2023. “America’s Crisis of Confidence: Rising Mistrust, Conspiracies, and Vaccine Hesitancy After COVID-  
604 19.” *The Survey Center on American Life* (blog). 2023.
- 605 78. National Institute for Health Care E. NICE Process and Methods Guides. *Developing NICE*  
606 *Guidelines: The Manual*. London: National Institute for Health and Care Excellence (NICE); 2015.
- 607 79. Fleming-Dutra KE, Wallace M, Moulia DL, Twentyman E, Roper LE, Hall E, et al. Interim  
608 Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and  
609 Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022.  
610 Centers for Disease Control and Prevention (CDC). June 2022;71(26):859-68.
- 611 80. World Health Organization (WHO) COVID-19 immunization in refugees and migrants: principles  
612 and key considerations: interim guidance, 31 August 2021. August 2021.
- 613 81. American College of Obstetricians and Gynecologists (ACOG) COVID-19 Vaccination  
614 Considerations for Obstetric–Gynecologic Care. May 2023.
- 615 82. Twentyman E, Wallace M, Roper LE, Anderson TC, Rubis AB, Fleming-Dutra KE, et al. Interim  
616 Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-  
617 19 Vaccine in Persons Aged ≥18 years — United States, July 2022. Centers for Disease Control and  
618 Prevention (CDC). August 2022;71(31):988-92.
- 619 83. World Health Organization (WHO) Interim recommendations for the use of the Janssen  
620 Ad26.COVS.2 (COVID-19) vaccine. June 2022.
- 621 84. World Health Organization (WHO) Interim recommendations for use of the Bharat Biotech  
622 BBV152 COVAXIN® vaccine against COVID-19: interim guidance, first issued 3 November 2021, updated  
623 15 March 2022. March 2022.
- 624 85. World Health Organization (WHO) Interim recommendations for use of the ChAdOx1-S  
625 [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII  
626 COVISHIELD™). March 2022.
- 627 86. World Health Organization (WHO) Interim recommendations for use of the inactivated COVID-19  
628 vaccine BIBP developed by China National Biotech Group (CNBG), Sinopharm. May 2021.
- 629 87. World Health Organization (WHO) Interim recommendations for use of the inactivated COVID-  
630 19 vaccine, CoronaVac, developed by Sinovac. March 2022.
- 631 88. World Health Organization (WHO) Interim recommendations for use of the Moderna mRNA-  
632 1273 vaccine against COVID-19. August 2022.
- 633 89. World Health Organization (WHO) Interim recommendations for use of the Novavax  
634 NVXCoV2373 vaccine against COVID-19. September 2022.
- 635 90. World Health Organization (WHO) Interim recommendations for use of the Pfizer–BioNTech  
636 COVID-19 vaccine, BNT162b2, under Emergency Use Listing. January 2022.
- 637 91. Rosenblum HG, Wallace M, Godfrey M, Roper LE, Hall E, Fleming-Dutra KE, et al. Interim  
638 Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent  
639 Booster Doses of COVID-19 Vaccines — United States, October 2022. Centers for Disease Control and  
640 Prevention (CDC). November 2022;71(45):1436-41.
- 641 92. World Health Organization (WHO) Schooling during COVID-19: recommendations from the  
642 European Technical Advisory Group for schooling during COVID-19, June 2021. June 2021.
- 643 93. Wallace M, Woodworth KR, Gargano JW, Scobie HM, Blain AE, Moulia D, et al. The Advisory  
644 Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19  
645 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021. Centers for Disease Control and  
646 Prevention (CDC). May 2021;70(20):749-52.

- 647 94. Woodworth KR, Moulia D, Collins JP, Hadler SC, Jones JM, Reddy SC, et al. The Advisory  
648 Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19  
649 Vaccine in Children Aged 5–11 Years — United States, November 2021. Centers for Disease Control and  
650 Prevention (CDC). November 2021;70(45):1579-83.
- 651 95. Mbaeyi S OS, Collins JP, Godfrey M, Goswami ND, Hadler SC, Jones J, Moline H, Moulia D, Reddy  
652 S, Schmit K, Wallace M, Chamberland M, Campos-Outcalt D, Morgan RL, Bell BP, Brooks O, Kotton C,  
653 Talbot HK, Lee G, Daley MF, Dooling K. The Advisory Committee on Immunization Practices' Interim  
654 Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States,  
655 2021. Centers for Disease Control and Prevention (CDC). November 2021;70.
- 656 96. Dooling K, Gargano JW, Moulia D, Wallace M, Rosenblum HG, Blain AE, et al. Use of Pfizer-  
657 BioNTech COVID-19 Vaccine in Persons Aged  $\geq 16$  Years: Recommendations of the Advisory Committee  
658 on Immunization Practices — United States, September 2021. Centers for Disease Control and  
659 Prevention (CDC). September 2021;70(38):1344-8.

660